By day 9, transcription levels were higher in the EBNA-LP mutants than the wild-types – the opposite of what would be predicted from the transfection-based studies – for CD21 and HES1, and also for IL7 (Fig 6D), which is not induced by EBNA2 upon EBV infection, but does bind EBNA2 at its promoter [14], suggesting that in this context, EBNA-LP may restrain EBNA2’s transactivation ability. This evidence concerns the gene CR2 and Epstein-Barr virus infection.